TCRX Company Profile and Key Details

Q: Who are the executives of TCRX?

Dr. Zoran Zdraveski J.D., Ph.D.Chief Legal Officer & Company Sec.Mr. David P. SouthwellPres, Chief Executive Officer & DirectorMs. Heather SavelleVice President of Investor RelationsMr. Brian Michael Silver J.D.Senior Vice President, Chief Financial Officer & TreasurerMr. Tomasz Kula Ph.D.Co-Founder & Member of Advisory BoardMr. Ray LockardSenior Vice President of Technical Operations & QualityMs. Ann HargravesSenior Vice President of HRDr. Shrikanta Chattopadhyay M.D.Senior Vice President of Medical & Translational MedicineDr. Debora Barton M.D.Chief Medical OfficerDr. Stephen J. Elledge Ph.D.Co-Founder & Chairman of Scientific Advisory BoardDr. Gavin MacBeath Ph.D.Chief Executive Officer, Director & Interim Principal Financial OfficerMr. Leiden DworakPrincipal Accounting OfficerDr. William Desmarais M.B.A., Ph.D.Chief Bus. Officer

NASDAQ : TCRX

TScan Therapeutics

$0.76

-0.0168-2.15%

At Close 4:00 PM

57.22

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

TScan Therapeutics, Inc. (TCRX) stock declined over -2.15%, trading at $0.76 on NASDAQ, down from the previous close of $0.78. The stock opened at $0.78, fluctuating between $0.75 and $0.78 in the recent session.

Stock Snapshot

0.78

Prev. Close

46.61M

Market Cap

0.7516

Day Low

-0.79

P/E Ratio

-0.96

EPS (TTM)

-0.98

Cash Flow per Share

0.78

Open

61.07M

Number of Shares

0.7809

Day High

83.56%

Free Float in %

2.3

Book Value

129.83K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 06, 2026	0.78	0.78	0.75	0.76	129.83K
Aug 05, 2026	0.74	0.78	0.74	0.78	298.62K
Aug 04, 2026	0.72	0.76	0.72	0.74	796.13K
Aug 03, 2026	0.76	0.78	0.72	0.72	438.44K
Jul 31, 2026	0.78	0.78	0.73	0.74	248.45K
Jul 30, 2026	0.76	0.78	0.74	0.76	414.32K
Jul 29, 2026	0.78	0.80	0.73	0.74	609.52K
Jul 28, 2026	0.77	0.77	0.73	0.77	717.26K
Jul 27, 2026	0.81	0.87	0.76	0.77	903.96K
Jul 24, 2026	0.87	0.89	0.79	0.79	1.1M
Jul 23, 2026	0.88	0.92	0.85	0.85	1.08M
Jul 22, 2026	0.94	0.96	0.90	0.90	496.33K
Jul 21, 2026	0.92	0.95	0.91	0.94	145.68K
Jul 20, 2026	0.94	0.97	0.89	0.92	299.48K
Jul 17, 2026	0.89	0.93	0.88	0.91	143.97K
Jul 16, 2026	0.91	0.97	0.88	0.90	651.7K
Jul 15, 2026	0.94	0.97	0.91	0.92	472.76K
Jul 14, 2026	1.04	1.04	0.91	0.93	1.64M
Jul 13, 2026	1.07	1.10	1.02	1.03	1.15M
Jul 10, 2026	1.06	1.10	1.02	1.09	968.74K

Contact Details

Waltham, MA 02451

United States

https://www.tscan.com 857 399 9500

About Company

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Stock Peers

ARGX

7.36+0.85%

argenx SE$875.30 REGN

3.53+0.46%

Regeneron Pharmaceuticals, Inc.$772.11 UTHR

13.93+2.68%

United Therapeutics Corporation$532.94 MDGL

-3.76-0.73%

Madrigal Pharmaceuticals, Inc.$510.36 VRTX

-0.8-0.17%

Vertex Pharmaceuticals Incorporated$484.03 PRAX

50.93+15.95%

Praxis Precision Medicines, Inc.$370.16 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

2.27+0.69%

BeOne Medicines AG$329.80 KRYS

-3.09-0.95%

Krystal Biotech, Inc.$322.69 LGND

-2.43-0.80%

Ligand Pharmaceuticals Incorporated$300.14

Frequently Asked Questions

What is the current TScan Therapeutics, Inc. (TCRX) stock price?

TScan Therapeutics, Inc. (NASDAQ: TCRX) stock price is $0.76 in the last trading session. During the trading session, TCRX stock reached the peak price of $0.78 while $0.75 was the lowest point it dropped to. The percentage change in TCRX stock occurred in the recent session was -2.15% while the dollar amount for the price change in TCRX stock was - $0.02.

TCRX's industry and sector of operation?

The NASDAQ listed TCRX is part of Biotechnology industry that operates in the broader Healthcare sector. TScan Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of TCRX?

Dr. Zoran Zdraveski J.D., Ph.D.
Chief Legal Officer & Company Sec.
Mr. David P. Southwell
Pres, Chief Executive Officer & Director
Ms. Heather Savelle
Vice President of Investor Relations
Mr. Brian Michael Silver J.D.
Senior Vice President, Chief Financial Officer & Treasurer
Mr. Tomasz Kula Ph.D.
Co-Founder & Member of Advisory Board
Mr. Ray Lockard
Senior Vice President of Technical Operations & Quality
Ms. Ann Hargraves
Senior Vice President of HR
Dr. Shrikanta Chattopadhyay M.D.
Senior Vice President of Medical & Translational Medicine
Dr. Debora Barton M.D.
Chief Medical Officer
Dr. Stephen J. Elledge Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Dr. Gavin MacBeath Ph.D.
Chief Executive Officer, Director & Interim Principal Financial Officer
Mr. Leiden Dworak
Principal Accounting Officer
Dr. William Desmarais M.B.A., Ph.D.
Chief Bus. Officer

How TCRX did perform over past 52-week?

TCRX's closing price is 6% higher than its 52-week low of $0.72 where as its distance from 52-week high of $2.57 is -70.3%.

How many employees does TCRX have?

Number of TCRX employees currently stands at 142.

Link for TCRX official website?

Official Website of TCRX is: https://www.tscan.com

How do I contact TCRX?

TCRX could be contacted at phone 857 399 9500 and can also be accessed through its website. TCRX operates from 830 Winter Street, Waltham, MA 02451, United States.

How many shares of TCRX are traded daily?

TCRX stock volume for the day was 129.83K shares. The average number of TCRX shares traded daily for last 3 months was 694.92K.

What is the market cap of TCRX currently?

The market value of TCRX currently stands at $46.61M with its latest stock price at $0.76 and 61.07M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	142
Beta	1.04
Sales or Revenue	$21.05M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	142
Beta	1.04
Sales or Revenue	$21.05M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

TCRX Company Profile and Key Details

TScan Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Key Takeaways

Price Forecast & Outlook